

### **MicroPort Received CFDA Approval for Newly Extended Specifications of Apollo Intracranial Arterial Stent System**

MicroPort NeuroTech is pleased to announce that newly extended specifications for Apollo Intracranial Arterial Stent System recently received official certification of regulatory approval from China Food and Drug Administration (CFDA).

### **MicroPort Received CE Approval for FireMagic™, EasyFinder™, EasyLoop™ and FireMagic™ 3D**

Shanghai MicroPort EP MedTech Co., Ltd., a subsidiary of MicroPort Group, is pleased to announce that the 4 products which are FireMagic™ radiofrequency...

### **Castor Branched Thoracic Aortic Stent Released in CEC2013**

During CEC2013, MicroPort Endovascular (Shanghai) Co., Ltd. held breakfast Satellite Symposia in Beijing National Convention Center on Nov 2nd during CEC2013(China Endovascular Course).

### **MicroPort Orthopedics Participated in COA Exhibition in Beijing**

COA2013 (Chinese Orthopedics Association) was held in Beijing National Convention Center from Nov 7th to 10th, 2013.

### **MicroPort Held the Third Patient Education Seminar**

Due to the irregular lifestyle, more and more people suffer from coronary heart problems.

### **MicroPort NeuroTech attended OCIN 2013**

OCIN 2013 (Oriental Conference of Interventional Neuroradiology), sponsored by Cerebral Vascular Center of Changhai Hospital and Second Military Medical University, was held in Shanghai from Oct 25th to 27th.

### **Ten Significant Events Impacted China Medical Device Industry in 2013**

MicroPort Scientific Corp (853), a Chinese leading high end medical equipment producer, has bought Wright Medical Group Inc's hip and knee implants business for US\$290 million.

#### **Contents**

MicroPort Received CFDA Approval for Newly Extended Specifications of Apollo Intracranial Arterial Stent System

MicroPort Received CE Approval for FireMagic™, EasyFinder™, EasyLoop™ and FireMagic™ 3D

Castor Branched Thoracic Aortic Stent Released in CEC2013


MicroPort Orthopedics Participated in COA Exhibition in Beijing

MicroPort Held the Third Patient Education Seminar

MicroPort NeuroTech attended OCIN 2013

Ten Significant Events Impacted China Medical Device Industry in 2013

## MicroPort Received CFDA Approval for Newly Extended Specifications of Apollo Intracranial Arterial Stent System



MicroPort NeuroTech is pleased to announce that newly extended specifications for Apollo Intracranial Arterial Stent System recently received official certification of regulatory approval from China Food and Drug Administration (CFDA). Apollo is researched and developed independently by MicroPort NeuroTech (Shanghai) Co., Ltd. ("MicroPort NeuroTech"). There are 13 new general specifications added to the existing 15 specifications. The extended product portfolio provides more selections for physicians and improves the safety and efficacy for the operation.

Apollo Intracranial Arterial Stent System was originally approved by CFDA in 2004, and was the first balloon-expandable intracranial stent for the treatment of brain stroke entirely developed and designed in China. Since its introduction in 2005, Apollo has been well received among the neurologist community and currently has 65% domestic market share.

Apollo stent structure is especially indicated for the anatomic features of intracranial vessels, achieving a perfect combination of radial strength and flexibility. The Rapid Exchange delivery catheter is designed to pass complex tortuous vascularity, presenting excellent trackability and reachability. Since its introduction Apollo has been used for treating brain stroke cases in more than 400 hospitals nationwide, and to date more than 20,000 patients have benefited from our product. Apollo also won second award of Shanghai Scientific and Technological Progress in 2009, and was named

Shanghai Key New Product in 2010.

Studies show that 10%-29% of cerebral ischemia are caused by intracranial atherosclerosis, and that each year, between 40,000-60,000 patients in the USA, suffer stroke caused by or related to intracranial artery stenosis. This accounts for about 10%-20% of all stroke patients, and treatment of atherosclerotic intracranial stenosis has become the major preventive measure for ischemic cerebrovascular disease.

*Back to Top*

## MicroPort Received CE Approval for FireMagic™, EasyFinder™, EasyLoop™ and FireMagic™ 3D



Shanghai MicroPort EP MedTech Co., Ltd., a subsidiary of MicroPort Group, is pleased to announce that the 4 products which are FireMagic™ radiofrequency ablation catheter, EasyFinder™ fixed or adjustable curved mapping catheter, EasyLoop™ circumferential pulmonary vein mapping catheter and FireMagic™ 3D saline infusion radiofrequency ablation catheter received CE certificate on Nov 20th 2013.

FireMagic™ radiofrequency ablation catheter is used in the cardiac electrophysiology diagnostic procedure and radiofrequency ablation. EasyFinder™ fixed or adjustable curved mapping catheter is mainly used in detailed mapping of electrical cardiac arrhythmia examination which detects different electrophysiological signal. EasyLoop™ circumferential pulmonary vein mapping catheter is used to detect and extract different signal in pulmonary

vein isolation, which is indispensable to the ablation procedure for the treatment of atrial fibrillation.


FireMagic™ 3D saline infusion radiofrequency ablation catheter is mainly used in ablation procedure by providing precise location of the catheter tip in the body and collecting cardiac ECG signal to help physician to effectively maneuver the ablation catheter in the body during the procedure. Currently, the procedure of catheter ablation is gaining wide acceptance in the treatment of atrial fibrillation. The use of FireMagic™ 3D combined with Columbus™ 3D cardiac mapping system provides physicians with a comprehensive solution for the diagnosis and treatment of complex arrhythmias. In addition, Columbus™ with FireMagic™ 3D is the only domestically developed 3D mapping system with the CE certificate.

According to the report from MILLENNIUM RESEARCH GROUP at EUROPEAN MARKETS FOR ELECTROPHYSIOLOGY MAPPING AND ABLATION DEVICES 2012, it is expected that the market for diagnostic catheter and ablation catheter will reach \$310 million in 2013. By the end of 2011, the patient population with atrial fibrillation reached 3.3 million in Europe. The procedure volume for atrial fibrillation treatment is expected to reach 36,000 cases in 2013 representing an annual growth rate of 15.1%. The CE approval with the products provides foundation in entering international market for MicroPort Group.



[Back to Top](#)

## Castor Branched Thoracic Aortic Stent Released in CEC2013



During CEC2013 (*China Endovascular Course*), MicroPort Endovascular (Shanghai) Co., Ltd. held breakfast Satellite Symposia in Beijing National Convention Center on Nov 2nd 2013. The theme of the Satellite Symposia was to introduce Castor branched thoracic aorta stent. Professor Zhong Chen, Director of Vascular Surgery Department in Beijing Anzhen Hospital and other specialists include Dr. Zhonghua Li, Deputy General Manager of MicroPort Endovascular were invited as guest speakers.

Professor Zhong Chen gave praise to MicroPort Endovascular for the work of research, development and innovation in the field of vascular surgery-related medical device products. He emphasized the fact that MicroPort is actually the first domestic medical device company specializes in vascular stent. It is truly a domestic rooted company and a symbol of national pride. Associate Professor Qingsheng Lu shared the clinical result of Castor stent with the guest speakers. Professor Weiliang Jiang introduced the applicable disease cases and indications for the use of Castor. All the guest speakers discussed the advantages and disadvantages of various surgical treatments of thoracic aortic dissection and clinical follow-up cases from the Harbin Second Hospital. The meeting was concluded with the remarks from Dr. Zhonghua Li talking about the future trend of MicroPort Endovascular.

[Back to Top](#)

## MicroPort Orthopedics Participated in COA Exhibition in Beijing

COA2013 (Chinese Orthopedics Association) was held in Beijing National Convention Center from Nov 7th to 10th, 2013. Senior leaders and other staff from MicroPort Orthopedics attended the meeting. MicroPort Orthopedics has greatly promoted its brand recognition during this COA meeting and facilitated the further advancement in the marketplace.

*[Back to Top](#)*

## MicroPort Held the Third Patient Education Seminar

Due to the irregular lifestyle, more and more people suffer from coronary heart problems. To better educate large population about the Coronary Artery Disease (CAD) and familiarize them with proper preventive measures, sales department from MicroPort held its third patient education seminar named "Heart Journey" throughout the China and opened educational centers in major provinces including Chongqing, Guangdong, Gansu, Hebei, Yunnan and others. Experts and specialists from various major hospitals jointed the education seminars to provide detailed information to the audiences.

*[Back to Top](#)*

Neuroradiology), sponsored by Cerebral Vascular Center of Changhai Hospital and Second Military Medical University, was held in Shanghai from Oct 25th to 27th.

Professor Liu Jianmin from Changhai Hospital and Li Minghua presented two keynote speeches on the theme "Application of Tubridge Flow Guide" and "Application of Willis Stent Graft". In the speech, two experts explained and commented on the safety and efficacy features of Tubridge and Willis based on a large amount of accumulated clinical data. A live surgical operation that used Tubridge and Willis was demonstrated during the meeting and left deep impression among the audiences.


*[Back to Top](#)*

## Excerption from Ten Significant Events Impacted China Medical Device Industry in 2013

MicroPort Scientific Corp (853), a Chinese leading high end medical equipment producer, has bought Wright Medical Group Inc's hip and knee implants business for US\$290 million. The deal becomes the largest multinational acquisition case in China's medical industry so far.

*[Back to Top](#)*

## MicroPort NeuroTech attended OCIN 2013



OCIN 2013 (Oriental Conference of Interventional